Xanthus Pharmaceuticals

Innovative treatments for cancer and autoimmune disorders through pioneering small-molecule therapeutics.

Add To Watchlist
General Information
Company Name
Xanthus Pharmaceuticals
Founded Year
2001
Location (Offices)
Founders / Decision Makers
Number of Employees
-
Industries
Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Series B
Social Media

Xanthus Pharmaceuticals - Company Profile

Xanthus Pharmaceuticals is a biopharmaceutical company founded in 2001 with a focus on discovering, developing, and commercializing small-molecule therapeutics for cancer and autoimmune disorders. The company's slogan reflects its dedication to pioneering innovative treatments for these challenging health conditions. Xanthus recently received a significant $25.00M Series B investment on 01 December 2006, with the funding coming from a diverse group of investors including HealthCare Ventures, GIMV, NeoMed Management, Kester Capital, Hambrecht & Quist Capital Management, The Still River Fund, GeneChem, CDIB BioScience Ventures, Yasuda Enterprise Development, and CDP Capital Technology Ventures. With this injection of funding, Xanthus Pharmaceuticals is well-positioned to continue its advancements in the biopharma, biotechnology, and pharmaceutical industries, furthering its mission to revolutionize treatment options for cancer and autoimmune disorders.

Taxonomy: Biopharmaceutical, Cancer treatment, Autoimmune disorders, Small-molecule therapeutics, Drug discovery, Drug development, Acquisition, Commercialization

Funding Rounds & Investors of Xanthus Pharmaceuticals (3)

View All
Funding Stage Amount No. Investors Investors Date
Series B $25.00M 10
HealthCare Ventures, investor in Xanthus Pharmaceuticals's Series B round GIMV, investor in Xanthus Pharmaceuticals's Series B round NeoMed Management, investor in Xanthus Pharmaceuticals's Series B round Kester Capital, investor in Xanthus Pharmaceuticals's Series B round Hambrecht & Quist Capital Management, investor in Xanthus Pharmaceuticals's Series B round The Still River Fund, investor in Xanthus Pharmaceuticals's Series B round
GeneChem, CDIB BioScience Ventures +2 		01 Dec 2006
Series B $30.80M - 12 Dec 2003
Series A $20.40M - 05 Feb 2003

Latest News of Xanthus Pharmaceuticals

View All

No recent news or press coverage available for Xanthus Pharmaceuticals.

Similar Companies to Xanthus Pharmaceuticals

View All
Congruence Medical Solutions - Similar company to Xanthus Pharmaceuticals
Congruence Medical Solutions Addressing compelling needs in injectable drug delivery
Bostal Drug Delivery - Similar company to Xanthus Pharmaceuticals
Bostal Drug Delivery Innovative drug delivery solutions enhancing the development and improvement of pharmaceuticals since 2013.
National Drug Screening, Inc. - Similar company to Xanthus Pharmaceuticals
National Drug Screening, Inc. Drug and alcohol testing programs for large and small employers.
Forensic Fluids Laboratories - Similar company to Xanthus Pharmaceuticals
Forensic Fluids Laboratories The Oral Fluid Drug Testing Specialists
MPR - Medical Professionals Reference - Similar company to Xanthus Pharmaceuticals
MPR - Medical Professionals Reference MPR provides daily drug news, medication safety alerts & recalls, and industry-supported drug information & education.
Circle Decoration Circle Decoration

Want to dive deeper into Xanthus Pharmaceuticals? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now